Αποτελέσματα Αναζήτησης
3 Νοε 2020 · New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment. Conclusion.
This article provides updated recommendations for the treatment of myasthenia gravis (MG) based on the latest evidence in the literature. It includes new recommendations for rituximab, eculizumab, methotrexate, and immune checkpoint inhibitor-associated MG.
19 Ιαν 2021 · New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.
9 Ιουν 2022 · The use of IVIG in MG provides an option for rapid improvement in critical deterioration, being preferred over more invasive and less available therapies such as plasmapheresis. For refractory MG, the addition of IVIG can improve a patient’s status and reduce the dosage of immunosuppressive medications.
Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion:
Intravenous immunoglobulin (IVIG) is an expensive and commonly used immunotherapy for patients with an exacerbation of MG, but its effectiveness has only recently been demonstrated in a randomized clinical trial.
20 Οκτ 2014 · Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. Majed Alabdali. , Carolina Barnett. , Hans Katzberg. , Ari Breiner. & Vera Bril. Pages 1659-1665 | Published online: 20 Oct 2014. Cite this article. https://doi.org/10.1586/1744666X.2014.971757. Full Article. Figures & data. References. Citations. Metrics.
